To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2016-0295 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fe/Mo-Based Lipid Peroxidation Nanoamplifier Combined with Adenosine Immunometabolism Regulation to Augment Anti-Breast Cancer Immunity.
Adv Mater
January 2025
Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, 87 DingJiaQiao Road, Nanjing, 210009, P. R. China.
Immunogenic cell death (ICD)-mediated immunization strategies have great potential against breast cancer. However, traditional strategies neglect the increase in the immunosuppressive metabolite, adenosine (ADO), during ICD, leading to insufficient therapeutic outcomes. In this study, it is found that the adenosine A2A receptor (A2AR) is significantly expressed in breast cancer and positively associated with regulatory T (Treg) cells.
View Article and Find Full Text PDFHabitat-based MRI radiomics to predict the origin of brain metastasis.
Med Phys
January 2025
Department of Scientific Research and Academic, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, P. R. China.
Background: This study aims to explore the value of habitat-based magnetic resonance imaging (MRI) radiomics for predicting the origin of brain metastasis (BM).
Purpose: To investigate whether habitat-based radiomics can identify the metastatic tumor type of BM and whether an imaging-based model that integrates the volume of peritumoral edema (VPE) can enhance predictive performance.
Methods: A primary cohort was developed with 384 patients from two centers, which comprises 734 BM lesions.
Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.
Breast Cancer Res Treat
January 2025
Department of Public Health Sciences, University of Virginia, 560 Ray C Hunt Dr., Room 2107, Charlottesville, VA, USA.
Purpose: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This study investigates these disparities in MBC treatment initiation, aiming to identify key factors crucial for improving timely access to care.
Method: Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with either De novo or relapsed MBC in the U.
Assessment of the functional and health-related needs of patients with metastatic breast cancer prior to initiation of cancer treatment.
Breast Cancer Res Treat
January 2025
University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Purpose: To identify needs of metastatic breast cancer patients prior to starting a new systemic treatment.
Methods: Fifty patients with newly diagnosed, recurrent, or progressive metastatic breast cancer completed an electronic survey which included patient-reported outcome measures of function (PROMIS Cancer Function Brief 3D profile), quality of life (FACT-G), exercise (Godin Leisure-Time exercise questionnaire), and diet (REAP-S); demographic information; and self-reported use of or referral to specific resources at the cancer center prior to beginning a new systemic oncologic treatment.
Results: Prior to starting a new treatment for metastatic breast cancer, patients reported mild functional impairment (PROMIS Cancer Function Brief 3D profile mean score:42.
Acceptability of the Fit2ThriveMB mHealth physical activity promotion intervention in women with metastatic breast cancer.
Support Care Cancer
January 2025
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 N Lake Shore Drive, Suite 1400, Chicago, IL, 60611, USA.
Purpose: Increasing physical activity (PA) is safe and associated with improved health outcomes in patients with metastatic breast cancer (MBC). Mobile health (mHealth) PA interventions that allow for remote monitoring and tailoring to abilities may be particularly useful for MBC patients. However, limited data exist on the acceptability of these interventions for MBC patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!